Overview 2019-10-18T11:14:38+01:00

Northern Alliance Advanced Therapies Treatment Centre

The Northern Alliance Advanced Therapy Treatment Centre (NA-ATTC), formally established in March 2018, is a consortium of twenty industry, NHS and academic organisations led by Newcastle Hospitals and the Scottish National Blood Transfusion Service (SNBTS). The purpose of the centre is to develop the systems and infrastructure required to support the delivery of cell and gene therapies with the ultimate aim of increasing patient access to advanced therapy medicinal products (ATMPs) on a national level.

NA-ATTC’s vision is to increase patient access to advanced therapy medicinal products (ATMPs) regionally and nationally by growing a cost-effective clinical delivery pathway which meets the needs of the providers of advanced therapy products. The centre has a patient reach of circa 15 million spanning the North of England and Scotland and is working across two healthcare systems.

The centre will focus on all elements of the clinical delivery pathway from procurement of starting materials, near patient GMP, distribution and administration through to delivery of clinical trials and adoption and reimbursement across a range of advanced therapies and indications. This will entail the participation and collaboration of nurses, medical clinicians, hospital pharmacists, NHS managers, clinical commissioners and companies.

Location

The NA-ATTC works across the north of England (Leeds and Newcastle upon Tyne) and Scotland.

Key Objectives

The key objectives of the NA-ATTC are to:

  • Identify all areas for improvement through gap analysis
  • Design, devise and implement solutions in these areas
  • Ensure that solutions are integrated across the clinical delivery pathway
  • Roll out and disseminate best practice regionally and nationally.

The Centre will deliver its objectives over 36 months via six Work Packages;

  1. Manufacturing and Preparation
  2. Supply Chain
  3. Patient-Centred Advanced Therapy Delivery
  4. Infrastructure, Reimbursement and Outcomes
  5. Wider Network Engagement
  6. Informatics

The Centre will develop best practice for safe and effective delivery of advanced therapies to patients. This will include robust and connected supply chains, tracking and tracing systems compliant with regulatory standards, patient follow up and data repositories and ultimately adoption and reimbursement based on clinical service delivery as well as product costs. A key component will be the use of informatics to achieve utility at scale in all elements of the clinical pathway, including product release.

The project will map Institutional Readiness Levels (IRLs; how far an organisation needs to adapt to embrace a new technology given pre-existing practices and infrastructure) for disruptive advanced therapies within the NA-ATTC and across the NHS and enable the therapies to achieve the highest IRLs within the time frame available. Close interaction between NA-ATTC, product and supply chain companies, regulators, health economists and healthcare commissioners will be essential to achieve this.

NA-ATTC’s innovative approach includes development with commercial partners of new and robust supply chains, tracking and capture processes, a harmonised Toolbox for procedures and processes, innovative training networks and novel ways to approach health and safety, including follow-up.

Leadership team

Neil Watson, Co-Director

Marc Turner, Co-Director

Finn Willingham, Operations Manager

Michael Whitaker, Steering Board Chair (Galen Biomed Ltd.)

Jim Shaw, Clinical Advisory Group Chair (Newcastle University)

Christopher Herbert, Leeds Teaching Hospitals NHS Foundation Trust

Andy Baker, Scientific Advisor (University of Edinburgh)

Christopher Vann, Senior Vice President, Chief Operating Officer, Autolus

Governance – Terms of Reference

The NA-ATTC is overseen by governance structures including a Steering Board, made up of representatives from each Partner Organisation, an Executive Team as detailed above, and a Clinical Advisory Group and Industry Advisory Group. Further details of these structures and their Terms of Reference are available below.

NA-ATTC Steering Board:

Steering Board

NA-ATTC Executive Team:

Executive Team

NA-ATTC Clinical Advisory Group:

Clinical Advisory Group

Clinical Advisory Group Membership

NA-ATTC Trial Coordination Unit

Trial Coordination Unit

Our partners

AHSN NENC

www.ahsn-nenc.org.uk
Dr Nicola Wesley, Interim Chief Executive Officer

Alcyomics Ltd

www.alcyomics.com
Professor Anne Dickinson, Founder and Director

GE Asymptote

https://www.gelifesciences.com
Dr John G Morris, Chief Executive Officer
Bill Shingleton, Alliances Manager

Autolus Therapeutics

www.autolus.com

Christopher Vann Senior Vice President, Chief Operating Officer

Helen Delahaye, Project Manager

Cell Medica

www.cellmedica.com
Karen Hodgkin, Chief Operating Officer

Chiesi Limited

http://chiesi.uk.com/rare-diseases
Julie De-Almeida, Head of Market Access UK & Ireland
Tom Chubb, Rare Disease Manager

Datatrial

www.datatrial.com
Julie Wright, Commercial Director
Jamie Pollard, Head of Software Development

NHS Greater Glasgow and Clyde

www.nhsggc.org.uk
Dr David Irvine, Consultant Haematologist
Dr Samantha Carmichael, Lead Pharmacist – Clinical Trials/R&D
Melanie McColgan, General Manager, Specialist Oncology and Clinical Haematology

Leeds Teaching Hospitals NHS Trust

www.leedsth.nhs.uk
Dr Christopher Herbert, Director of Operations for Research and Innovation
Professor Gordon Cook, Professor of Haematology and Myeloma Studies
Dr Beki James, Consultant Paediatric Haematologist
Debbie Beirne, Manager and Deputy Director of the NIHR Leeds Clinical Research Facility

Milteyni Biotec

www.milteynibiotec.com
Michele Giroux, UK General Manager

Newcastle University

www.ncl.ac.uk
https://www.ncl.ac.uk/icm/research/
https://www.ncl.ac.uk/ctf/
Professor Jim Shaw, Professor of Regenerative Medicine
Professor Anne Dickinson, Strategic Research Adviser

NHS Blood and Transplant

www.nhsbt.nhs.uk
Jon Smythe, Head of Cellular and Molecular Therapies

Dr Sandeep Kumar, Cell Therapy Advanced Specialist

NHS Lothian

www.nhslothian.scot.nhs.uk
Professor Timothy Walsh, Head of Section/Lead of Edinburgh Critical Care Research Group, R&D Director – NHS Lothian

The Newcastle upon Tyne Hospitals NHS Foundation Trust

www.newcastle-hospitals.org.uk
Neil Watson, Clinical Director of Pharmacy and Medicines Management and Co-Director of the NA-ATTC
Dr Finn Willingham, Operations Manager, NA-ATTC
David Caulfield, Assistant Director of Pharmacy, QA
Anne Black, Regional QA Specialist/Lead for Newcastle Therapeutics

RoslinCT

www.roslinct.com
Janet Downie, Chief Executive Officer

Scottish National Blood Transfusion Service

www.scotblood.co.uk
Professor Marc Turner, Medical Director SNBTS and Co-Director of the NA-ATTC
Professor John Campbell, Associate Director – Tissues, Cells and Advanced Therapeutics
Ewan Morrison, Director of Pharmacy, National Services Scotland

Fisher Bioservices

www.fisherbioservices.com
Richard Bazell, Supervisor, Client Services
Christopher Stone, Supervisor, Client Services
Neil Ridley, Consultant Project Director
Luke Wilson, Lead Account Manager

TrakCel

www.trakcel.com
Dr Matthew Lakelin, Chief Scientific Officer
Ben Innes, Project Manager

University of Edinburgh

https://www.ed.ac.uk/
http://www.crm.ed.ac.uk/research/group/liver-stem-cells-and-regeneration
https://www.cvs.ed.ac.uk/research
Prof Stuart Forbes, Director, Scottish Centre for Regenerative Medicine (SCRM), WP3 Co-Lead, Clinical Advisory Group Clinician Scientist Lead
Prof Andy Baker, Scientific Advisor
Lisa Wotherspoon, Advanced Therapies Clinical Trial Coordinator

World Courier

www.worldcourier.com
Simon Ellison, Cell and Gene Therapy Service Director

Visit our other centres